Clinical Trials Browser

NCT05411380 2022-11-04

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Phase 2 Unknown

73 enrolled

Breast

Breast Neoplasms

NCT05253066 2022-02-23

Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

Phase 2/3 Unknown

130 enrolled

Breast

Breast Neoplasms

NCT03538171 2021-07-09

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Phase 3 Unknown

375 enrolled

Breast

Advanced Breast Cancer

NCT00541086 2020-02-07

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Phase 3 Unknown

3,697 enrolled

Breast

Breast Neoplasms

NCT02109913 2019-10-14

Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane

Phase NA Unknown

175 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03024580 2019-08-15

MEGA

Phase 2 Unknown

20 enrolled

Breast

Breast Neoplasms

NCT04023292 2019-07-17

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Phase 2 Unknown

185 enrolled

Breast

Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

Phase 2 Unknown

250 enrolled

Breast

Breast Diseases, Breast Neoplasms

NCT02592746 2019-04-08

A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC

Phase 2 Unknown

182 enrolled

Breast

Breast Neoplasms

NCT03137368 2018-10-31

STEP

Phase 3 Unknown

300 enrolled

Breast

Breast Neoplasms

NCT02689921 2018-09-28

NEOADAPT

Phase 2 Unknown

7 enrolled

Breast

Breast Neoplasms

NCT02910050 2017-12-22

BETTER

Phase 2 Unknown

58 enrolled

Breast

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02467686 2017-03-20

Cimicifuga

Phase 4 Unknown

60 enrolled

Sexuality

NCT02646735 2017-01-02

FRIEND

Phase 2 Unknown

148 enrolled

Breast

Breast Neoplasms

NCT01655004 2016-06-22

Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD

Phase NA Unknown

110 enrolled

Breast

Breast Neoplasms

NCT02404051 2016-06-15

FEVEX

Phase 3 Unknown

745 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02025712 2014-01-01

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Phase 2 Unknown

35 enrolled

BreastOther neoplasm

Hormone Receptor Positive Malignant Neoplasm of Breast

NCT00003418 2013-12-19

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer

Phase 3 Unknown

4,400 enrolled

Breast

Breast Neoplasms

NCT00688194 2013-08-26

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

Phase 3 Unknown

396 enrolled

Breast

Breast Neoplasms

NCT00931450 2013-08-12

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

Phase 1/2 Unknown

70 enrolled

Breast

Breast Neoplasms

NCT01431053 2013-03-13

Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

Phase 2 Unknown

160 enrolled

Breast

Breast Neoplasms

NCT01648608 2012-08-03

Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer

Phase 2/3 Unknown

600 enrolled

Breast

Breast Neoplasms

NCT00687648 2009-06-17

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 2 Unknown

70 enrolled

Breast

Breast Neoplasms

NCT00902954 2009-05-15

LEANEX

Phase 3 Unknown

540 enrolled

Breast

Breast Neoplasms